Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Content Format:

Multimedia

Credit Type:

ABIM MOC | ACPE | AMA | ANCC

Credits:

1.00
Personalized Treatment Options From 5 Experts for People With CLL

Content Format:

Tool

Credit Type:

--

Credits:

--
ExpressPoints:Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Evolving CLL Treatment Recommendations

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

0.75
Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Expert Guidance for the Treatment of CLL

Content Format:

Tool

Credit Type:

--

Credits:

--
Evolution in Expert Recommendations for CLL Treatment

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Evolution in Expert Recommendations for CLL Treatment

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Multidisciplinary Perspectives on CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

0.75
Multidisciplinary Perspectives on Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

0.50
CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
CLL-Related Symptoms and Managing Adverse Events with BTK Inhibitors

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Expert Answers to Frequently Asked Questions About Chronic Lymphocytic Leukemia and COVID-19

Content Format:

Text Module

Credit Type:

--

Credits:

--
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
My Take on Key Therapy Issues for Patients With CLL During COVID-19

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
ExpressPoints Chronic Lymphocytic Leukemia: New Horizons with BTK Inhibitors

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
COVID-19 Implications for Patients with CLL: Living Slideset

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
BTK Inhibitors in Relapsed/Refractory CLL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
My Thoughts on the Recent FDA Approval of Acalabrutinib in CLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Expert Guidance on Personalizing Treatment of CLL: Overcoming the Conundrum of Multiple New Agents

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Prescription for More CLL Information

Content Format:

PDF

Credit Type:

--

Credits:

--